We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

BIOHIT Healthcare OY

Offers technologies and services for diagnosing and preventing gastrointestinal diseases and associated risks read more Featured Products: More products

Download Mobile App




Biohit's GastroPanel Blood Test Accurately Diagnoses Hp Infection and AG Before Endoscopy

By HospiMedica International staff writers
Posted on 09 May 2022
Print article
Image: GastroPanel test is meant for diagnosis of AG and Hp infection in patients referred for gastroscopy (Photo courtesy of Biohit Oyj)
Image: GastroPanel test is meant for diagnosis of AG and Hp infection in patients referred for gastroscopy (Photo courtesy of Biohit Oyj)

Helicobacter pylori (Hp) infection, atrophic gastritis (AG) and high acid output are important risk factors for gastric and esophageal cancers. Now, the latest study to evaluate the diagnostic accuracy of a unique blood test for the diagnosis of both AG and Hp infection in patients referred for gastroscopy from primary care with different indications has confirmed its high accuracy.

Biohit Oyj’s (Helsinki, Finland) new generation GastroPanel test is designed for the first-line diagnosis of Hp infection and AG in patients with upper abdominal symptoms, such as dyspepsia and gastro-oesophageal reflux disease (GORD), before endoscopy. GastroPanel is also the only test on the market capable of monitoring the regulatory mechanism of acid output in the stomach. The new generation (unified) GastroPanel test works on the same principle as the original GastroPanel ELISA test and is designed to harmonize the ELISA processing conditions of four biomarkers.

The highly informative GastroPanel assay is a cost-effective solution for population-based screening for the risk of gastric cancer in asymptomatic and symptomatic individuals, and its efficacy has already been confirmed by several studies in both high- and low-risk countries. Along with the previously published clinical validation studies, the latest biopsy-confirmed study was designed to verify the diagnostic capabilities of the new generation GastroPanel test compared to the current gold standard (gastroscopy and biopsy analysis), and to demonstrate its performance was comparable to the original GastroPanel test. The positive results from the study pave the way for BIOHIT’s new GastroPanel Quick Test (point of care test) which will be launched in Q1 2022.

“A total of 522 patients referred for gastroscopy at the Gastro Centre, OUH, were consented and enrolled for this particular study,” said Dr. Olli-Pekka Koivurova, Principal Investigator of the study. "Blood was sampled for all patients using the GastroPanel test, along with performing quality-controlled gastroscopies with mucosal biopsies. The results confirmed that the new generation GastroPanel is a highly accurate test for the non-invasive diagnosis of AG and Hp infection in patients referred for diagnostic gastroscopies.”

Related Links:
Biohit Oyj

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Bronchoscope
EB-500

Print article

Channels

Surgical Techniques

view channel
Image: Miniaturized electric generators based on hydrogels for use in biomedical devices (Photo courtesy of HKU)

Hydrogel-Based Miniaturized Electric Generators to Power Biomedical Devices

The development of engineered devices that can harvest and convert the mechanical motion of the human body into electricity is essential for powering bioelectronic devices. This mechanoelectrical energy... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.